Protect your adolescent and adult patients from serogroup B meningococcal disease
We are very pleased to announce the addition of our newest vaccine vendor partner – PFIZER. CASA members may now choose to participate in the Pfizer program to receive CASA member discounts on Trumenba® (Meningococcal Group B Vaccine) that is now available for use in the United States.
Trumenba is a new FDA-approved vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
Trumenba is approved based upon demonstrated immune response against four group B strains representative of prevalent strains in the United States. The effectiveness of Turmenba against diverse group B strains has not been confirmed. Now, with Trumenba, you can help protect your adolescent and you adult patients from serogroup B meningococcal disease. Trumenba is now available.